Fig. 4From: Afatinib helped overcome subsequent resistance to osimertinib in a patient with NSCLC having leptomeningeal metastasis baring acquired EGFR L718Q mutation: a case reportTreatment timeline. *Exploring therapeutics included the following: high-dose icotinib pulsatile therapy, temozolomide oral administration, and bevacizumab intrathecal injection. BSC, Best supportive careBack to article page